Jade Biosciences 3Q 2026: EPS ($0.42) — 10-Q Summary
Jade Biosciences reported a wider net loss of $35.06M in Q3 2026, with no revenue and higher operating expenses. Diluted EPS was ($0.42). The company has $475.7M in cash and expects it to last 12 months. Clinical trials for JADE101, JADE201, and JADE301 are ongoing, with data expected in 2027.
How this was made

The 30-second read
Why it matters
The earnings miss may trigger short‑term price declines, but the cash position and upcoming trial data provide potential upside catalysts.
Market read
Primary earnings disclosure for a micro‑cap biotech; relevant for short‑term traders and longer‑term investors monitoring trial pipelines.
What to watch
Upcoming Phase 2 data for JADE101 and Phase 1 data for JADE201 could catalyze a rebound if results are positive.
Background
Jade Biosciences filed its Q3 2026 10‑Q, reporting widened losses, no revenue, and cash sufficient for 12 months.
Ticker impact
Q3 2026 net loss widened to $35.06M, EPS -$0.42, cash $475.7M, no revenue reported.
likely downward pressure as market prices in widened loss and lack of revenue
The 10‑Q shows a larger net loss and no revenue, which typically triggers sell‑offs in biotech stocks.
Market effects
Biotech sector may see modest pullback as earnings miss highlights funding pressures.
US biotech investors may adjust exposure; limited broader market effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The sizable cash runway ($475M) could support upcoming trials, offering a longer‑term upside despite the loss.
Key entities
- companyJade Biosciences, Inc.
US‑listed biotech focused on renal and autoimmune therapies.